BIND Therapeutics Appoints Andrew Hirsch as President and Chief Executive Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BIND Therapeutics (BIND) Appoints Andrew Hirsch as Permanent CEO
June 22, 2015 10:17 AM EDTBIND Therapeutics (Nasdaq: BIND) announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected to BINDs Board of Directors.
After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the Companys growth, said Daniel Lynch, Chairman, BIND Therapeutics Board of Directors. His vision, operational philosophy and experience are ideally suited for the... More
